DUBLIN–(BUSINESS WIRE)–The “AXL Kinase Inhibitor – Pipeline Insight, 2022” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This “AXL Kinase Inhibitor – Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
AXL Kinase Inhibitor: Overview
AXL receptor tyrosine Kinase is a member of the tyrosine-protein Kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein Kinase Mer family of receptor tyrosine Kinases. AXL is a member of a complex signaling network that is involved in the control of cell proliferation and differentiation. AXL is widely expressed in healthy tissues, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis.
AXL has emerged as a novel biomarker due to its role in biological processes and tumorigenesis. Because of the pleiotropic role of AXL in tumor pathophysiology and drug resistance, AXL represents a promising therapeutic target in the management of cancer. AXL inhibitors have been shown to potentiate tumor cell apoptosis and suppress migration and invasion. Targeting AXL enhances the therapeutic efficacy of chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase Inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase Inhibitor.
AXL Kinase Inhibitor Emerging Drugs Chapters
This segment of the AXL Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
AXL Kinase Inhibitor Emerging Drugs
Bemcentinib: BerGenBio / Rigel Pharmaceuticals
Bemcentinib (BGB324) is a potent, selective and orally bioavailable AXL inhibitor and a potential future cornerstone to therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. The drug is in phase II program, focused on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy.
Sitravatinib: Mirati Therapeutics
Sitravatinib is an oral, potent, spectrum-selective RTK inhibitor. It inhibits several closely related RTKs, including the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT. This inhibition weakens the cancer’s defenses in the tumor microenvironment.
AXL Kinase Inhibitor: Therapeutic Assessment
This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:
Major Players working on AXL Kinase Inhibitor
There are approx. 15+ key companies which are developing the AXL Kinase Inhibitor. The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.
Key Players
- BerGenBio
- Rigel Pharmaceuticals
- Mirati Therapeutics
- Ipsen
- SignalChem Lifesciences
- Arcus Biosciences
- Symphogen
- Qurient Co
- Daiichi Sankyo Company
- Aravive
- Exelixis
Key Products
- Bemcentinib
- Sitravatinib
- Cabozantinib
Research Programme: TAM inhibitors
Research Programme: AXL receptor tyrosine kinase inhibitors
- Sym 028
- Q-702
- AB 329
- Aravive S6
- XL092
Key Topics Covered:
Introduction
Executive Summary
AXL Kinase Inhibitor: Overview
- Structure
- Mechanism of Action
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
AXL Kinase Inhibitor – Analytical Perspective
In-depth Commercial Assessment
- AXL Kinase Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends
AXL Kinase Inhibitor Collaboration Deals
- Company-Company Collaborations (Licensing / Partnering) Analysis
- Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
- Comparative Analysis
Sitravatinib: Mirati Therapeutics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Bemcentinib: BerGenBio/Rigel Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
Early Stage Products (Phase I)
- Comparative Analysis
AB 329: Daiichi Sankyo Company
- Product Description
- Research and Development
- Product Development Activities
Pre-clinical and Discovery Stage Products
- Comparative Analysis
Q-702: Qurient Co
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
AXL Kinase Inhibitor Key Companies
AXL Kinase Inhibitor Key Products
AXL Kinase Inhibitor- Unmet Needs
AXL Kinase Inhibitor- Market Drivers and Barriers
AXL Kinase Inhibitor- Future Perspectives and Conclusion
AXL Kinase Inhibitor Analyst Views
AXL Kinase Inhibitor Key Companies
Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/waxump
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900